Bangalore, 26th of November, 2024 : Medtronic, a global leader in healthcare technology, announced the India launch of the InterStim X™ Sacral Neuromodulation (SNM) system for the treatment of overactive bladder (OAB), chronic fecal incontinence (FI), and non-obstructive urinary retention. The InterStim X™ system offers personalized sacral nerve stimulation therapy.
Sacral neuromodulation is an advanced therapy for people with bladder and bowel control issues that are not responding to other non-invasive therapies. The system works by targeting nerve signals that regulate bladder functions, which may reduce symptoms of incontinence – such as frequent trips to the bathroom and accidents. Patients can try the InterStim™ X system with an evaluation phase before they decide to have the system implanted, and it’s reversible if they change their Sacral neuromodulation procedure is performed in two stages. During the first stage, the lead is implanted and connected to an external stimulator to check therapeutic response for a period of 3-5 days. In stage II, the lead is connected to a subcutaneous implantable pulse generator (IPG) which is like a pacemaker. The IPG sends electrical signals via the lead which then signals the brain for voiding and control.
The InterStim™ X device and systems features:
· Proprietary 5th generation battery that offers more than 10 years of battery life without the need to recharge. With low energy settings, the device can last up to 15 years.
· The smart programmer is a device that resembles a common smartphone and has the capability of allowing patients to discreetly and independently adjust their choice of 11 therapy settings at home or on-the-go.
· SureScan™ technology that enables full body 1.5T and 3T MRI scans under certain conditions, which means that the latest imaging techniques can be availed when needed to diagnose disease, plan treatment, and monitor treatment progress. The MRI mode can be easily activated or deactivated by the patient using the smart programmer under the guidance of their physician.
“Medtronic is committed to advancing the standard of care of bladder and bowel control treatment and improving patient outcomes,” said Prateek Tiwari, Sr Director – Neuroscience & Specialty Therapies, Medtronic India. “With the introduction of the new recharge-free InterStim X, patients can get a decade or more of treatment for their bladder or bowel control issues from the only SNM system to be backed by over 90 clinical studies and over 1,000 clinical articles. It has been our endeavor to expand access to proven nerve stimulation therapies for the benefit of Indian patients with bladder and bowel control issues.”
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. Nothing contained herein is meant to be construed as medical advice and patients should speak to their physicians in regards their condition.
References:
1 Feloney MP, Stauss K, Leslie SW. Sacral Neuromodulation. [Updated 2024 Apr 18]. In: Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2024 Jan-.
2 Medtronic InterStim™ Micro SureScan™ MRI rechargeable neurostimulator with Overdrive™ battery technology Implant Manual. Document M978287A003 Rev A
3 Hull T, Giese C, Wexner SD, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56(2):23
4 Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015; 34:224-230
5 Leede Research, “Views on OAB: A Study for the National Association of Continence.” December 16, 2015
About The Author
More Stories
2024 Recap: Real Estate Sector Maintained Growth Momentum.
Reliance Retail Joins Hands With Department Of Consumer Affairs To Reaffirm Commitment To Consumer Safety.
Toyota Kirloskar Motor Unveils “Happier Paths Together” – A Corporate Campaign Championing Happiness For All.